MARKET

HROW

HROW

Harrow Health Inc
NASDAQ
33.83
-1.55
-4.38%
After Hours: 34.11 +0.28 +0.83% 19:42 03/27 EDT
OPEN
35.24
PREV CLOSE
35.38
HIGH
35.24
LOW
33.50
VOLUME
758.92K
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
20.85
MARKET CAP
1.26B
P/E (TTM)
-241.9886
1D
5D
1M
3M
1Y
5Y
1D
Harrow Health Expands Senior Notes Offering for Growth
TipRanks · 19h ago
Harrow issues $50 million 8.625% senior notes due 2030; offering grows total 2030 notes to $300 million
Reuters · 20h ago
ProKidney appoints Greg Madison chief commercial officer; senior leadership team expands
Reuters · 2d ago
Craig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)
TipRanks · 3d ago
Harrow Health Prices $50 Million Senior Notes Offering
TipRanks · 3d ago
Harrow prices $50M senior unsecured notes due 2030 at 8.625%
Seeking Alpha · 3d ago
Harrow prices USD 50 million 8.625% senior unsecured notes due 2030
Reuters · 3d ago
Press Release: Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Dow Jones · 3d ago
More
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Webull offers Harrow Inc stock information, including NASDAQ: HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.